06160 BEIGENE
- 100.800
- +6.000+6.33%
BEIGENE News
BeiGene (06160)'s total revenue for the first quarter reached US$752 million, up 68% year-on-year
BeiGene (06160) announced results for the first quarter of 2024, with total revenue reaching US$752 million, up 68% year on year; of these, product revenue reached US$747 million, up 82% year on year. Gross profit was approximately US$627 million, up 71.23% year over year. The adjusted operating loss was approximately US$147 million, a decrease of 47% over the previous year. R&D expenses were approximately US$460 million, an increase of 13% over the previous year. The net loss was approximately US$251 million, a year-on-year decrease of 27.9%.
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up
Beigene (HKG:6160) posted a net loss of $251.2 million for the first quarter of 2024, compared with a net loss of $348.4 million in a year-ago quarter, according to a Thursday filing on the Hong Kong
The biomedical sector of Hong Kong stocks strengthened, and BaiGene rose more than 5%
Glonghui, May 9 | BeiGene's increase extended to more than 5%, Pharmaceutical Biotech and Rongchang Biotech rose nearly 3%, and Cansino Biotech rose more than 1%.
Changes in Hong Kong stocks | BeiGene (06160) opened more than 3%, and total revenue in the first quarter increased nearly 70% year-on-year, Baiyuze's global growth was strong
BeiGene (06160) opened more than 3% higher. As of press release, it rose 3.38% to HK$98, with a turnover of HK$2,334,300.
The Hang Seng Index opened 0.04% lower for Hong Kong stocks, and the Hang Seng Technology Index opened 0.06% higher. BeiGene's total revenue for the first quarter reached US$752 million, up 68% year over year.
The Hang Seng Index opened 0.04% lower for Hong Kong stocks, and the Hang Seng Technology Index opened 0.06% higher. BeiGene's total revenue for the first quarter reached US$752 million, up 68% year over year.
Featured announcements | BeiGene's Q1 revenue increased nearly 70% year on year; GAC's sales fell nearly 25% year on year in April
① BeiGene's revenue increased by nearly 70% in the first quarter. What is the profit situation? ② GAC's sales volume fell by about 24% during the year. How much was the impact on sales in April?
Hong Kong Stock Announcement Nuggets | BeiGene's total revenue for the first quarter reached US$752 million, up 68% year over year
Meigaoyu (01985) plans to establish two companies, “Meigaoyu Artificial Intelligence” and “Hi-Tech Development” to promote the strategic layout of artificial intelligence...
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
Health care stocks were leaning lower pre-bell Wednesday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.8%. Teva Pharmaceutical Industries
BeiGene's revenue increased by nearly 70% in the first quarter, and GAC's sales fell by about 24% during the year | Selected Hong Kong Stock Announcements on May 8
① BeiGene's revenue increased by nearly 70% in the first quarter. What is the profit situation? ② GAC's sales volume fell by about 24% during the year. How much was the impact on sales in April?
Express News | BeiGene: Adjusted operating loss of US$147 million in the first quarter
BeiGene Announces Financial Results and Business Progress for the First Quarter of 2024
Total revenue for the first quarter reached US$752 million, with product revenue reaching US$747 million, with global sales reaching US$489 million, thanks to sales growth of 153% and 243% year-on-year in the US and Europe, respectively; with the recent approval of the FDA for the fifth indication, Baiyueze has now become the most widely indicated BTK inhibitor among similar drugs to rapidly advance the post-hematology pipeline; sonrotoclax is being developed as a monotherapy and a combination therapy with the core drug Baiyueze; BTK CDAC's Key research projects
BeiGene's first quarter revenue rose more than 70% year over year, and the winning rate of zebutinib infringement cases is expected to be over 50%
① BeiGene received product revenue of 5.325 billion yuan in the first quarter, an increase of 89.6% over the same period last year; ② “The US Patent and Trademark Office approved the company's application to review the patent that Pharmacyclics alleges the company infringed in the patent infringement lawsuit after authorization, and indicated that the company has proven that the patent is more than 50% likely to be invalid.”
Sales of self-developed products increased by BeiGene (688235.SH) in the first quarter, product revenue surged 89.6% to 5.325 billion yuan
BeiGene (688235.SH) Announces Disclosure of Key Financial Data for the First Quarter of 2024, 2024...
BeiGene (06160.HK)'s total revenue for the first quarter reached US$752 million, up 68% year-on-year
BeiGene (06160.HK) announced results for the first quarter of 2024, with total revenue of US$752 million, up 68% year on year; of these, product revenue reached US$747 million, up 82% year on year. Gross profit was approximately US$627 million, up 71.23% year over year. The adjusted operating loss was approximately US$147 million, a decrease of 47% over the previous year. R&D expenses were approximately US$460 million, an increase of 13% over the previous year. The net loss was approximately US$251 million, a year-on-year decrease of 27.9%.
BeiGene (06160.HK)'s product revenue increased 82% in the first quarter, and R&D expenses reached US$460 million and ranked among the top 15 global oncology treatment innovators
On May 8, GLONGHUI | BeiGene (06160.HK) announced that in the first quarter of 2024, the company's total revenue reached 752 million US dollars, of which product revenue reached 747 million US dollars, an increase of 82% over the previous year. Baiyueze's global sales reached US$489 million, thanks to sales growth of 153% and 243% year-on-year in the US and Europe, respectively. With the recent approval of the FDA for the fifth indication, Baiyueze has now become the most widely indicated BTK inhibitor among similar drugs. In the first quarter of 2024, Baizean's sales reached US$145 million, an increase of 26% over the previous year. Announced to win
BEIGENE: INSIDE INFORMATION -UNAUDITED RESULTS FOR THE THREE MONTHSENDED MARCH 31, 2024 OFBEIGENE, LTD. AND BUSINESS UPDATES
BeiGene (06160) Product revenue reached 5.3 billion yuan in the first quarter of 2024, and operating losses narrowed further
In the first quarter of 2024, BeiGene continued to show strong global development resilience, and the results of global commercialization of its approved products continued to be realized.
BeiGene's Q1 Loss Narrows as Revenue Rises
BeiGene (BGNE) reported a Q1 loss Wednesday of $2.41 per American depository share, narrowing from a loss of $3.34 a year earlier.
BeiGene GAAP EPADS of -$2.41 Beats by $0.48, Revenue of $751.65M Beats by $76.42M
Analysis
Price Target
No Data
